Alector Inc

Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Alector Inc reports robust earnings, advances Alzheimer's therapy development

Alector Inc's Q2 2023 earnings call highlighted strong financial performance, progress in late-stage clinical programs, and a focus on immuno-neurology research.
The company faces challenges in trial management and disease progression variability but benefits from a solid cash position and collaboration revenue.
Opportunities lie in upcoming milestones, conference participation, and the potential of AL002 therapy, positioning Alector for continued growth and innovation.

Alector Inc reports strong Q4 performance and advances in neurodegenerative treatments

Alector Inc's Q4 performance reflects significant achievements in late-stage programs, strong financial standing, and positive patient engagement, underlining progress in neurodegenerative disease treatment.
The company's strengths in immuno-neurology, blood-brain barrier technology, and strategic partnerships position them well for addressing Alzheimer's disease and exploring accelerated approval pathways.
Challenges in trial design, biomarker assessment, and resource allocation require careful navigation, while opportunities in therapeutic delivery enhancement and disease progression slowing offer avenues for growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Alector (ALEC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Alector (ALEC) Surges 8%: Is This an Indication of Further Gains?

Biotech companies have seen an economic boom lately thanks to the COVID-19 Pandemic and the need for effective treatments. Alector has benefited from the same positive trend in financials despite being one of the few companies not targeting COVID-19 treatments.

Alector, Inc: A Newer Biotech Company With Big Potential

Alector develops innovative therapeutic approaches for treating neurodegeneration. It is a critical stage biotechnology company.

Alector, Inc: A stock with its eyes on the future

SOUTH SAN FRANCISCO, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the appointment of Sara Kenkare-Mitra, Ph.D., as President and Head of Research and Development. In this newly created role, Dr. Kenkare-Mitra will lead all aspects of the company's immuno-neurology and oncology R&D efforts, including oversight of the research, development, clinical, manufacturing, regulatory, and related functions. Dr. Kenkare-Mitra will report to Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector.

Alector Announces Appointment of Sara Kenkare-Mitra, Ph.D., as President and Head of Research and Development

TAMPA, Fla.--(BUSINESS WIRE)---- $ALEC #AL001--Alzamend Neuro Announces Date for Delivery of Topline Data for Phase 1 First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer's

Alzamend Neuro Announces Date for Delivery of Topline Data for Phase 1 First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer's

Progranulin Levels Increase to Normal Ranges

Alector Presents Encouraging New AL001 Data from the Symptomatic FTD-GRN Cohort of INFRONT-2 Phase 2 Open-label Clinical Study

Preclinical Oncology Program Highlights Alector's Expertise  in Harnessing Components of the Innate Immune System to Impact Disease

Alector Presents Preclinical Data from AL009 Multi-Siglec Inhibitor Program at the Society for Immunotherapy of Cancer's 36th Annual Meeting

Alector (ALEC) delivered earnings and revenue surprises of -50.00% and -55.23%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Alector (ALEC) Lags Q3 Earnings and Revenue Estimates

Company to Host Analyst and Investor Conference Call on November 12 at 4:00 p.m. ET

Alector to Present New Data from Multiple Pipeline Programs at 2021 CTAD Conference and SITC Annual Meeting

Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Alector (ALEC) Earnings Expected to Grow: Should You Buy?

Alector develops immunology targets for neurodegenerative diseases. It recently signed up for a $2.2bn deal with GSK.

Alector: The GSK Deal Is A Major Value Add

SOUTH SAN FRANCISCO, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the addition of Elizabeth (Betsy) A. Garofalo, M.D., to the Company's Board of Directors. Dr. Garofalo is a veteran biopharmaceutical executive with more than 25 years of experience in global clinical development and regulatory affairs, with a focus on neurology.

Alector Announces Appointment of Elizabeth A. Garofalo, M.D.

There has been a major shakeup in the C-suite.

Why Alector Shares Are Diving Today

Planned Transitions Announced for Shehnaaz Suliman, M.D., MBA, MPhil, President and Chief Operating Officer and Robert Paul, M.D., Ph.D., Chief Medical Officer

Alector Provides Executive Leadership Update

Presented twelve-month data from ongoing AL001 open-label Phase 2 study in FTD-GRN at the 2021 Alzheimer's Association International Conference (AAIC)

Alector Reports Second Quarter 2021 Financial Results

Alector Inc (NASDAQ: ALEC) detailed early data from its lead drug, AL001, INFRONT-2 Phase trial at the Alzheimer's Association International Conference (AAIC 2021) Patients with one type of frontotemporal dementia decline because they're missing one copy of an immune-regulating gene called progranulin and subsequently have half the amount of the protein healthy adults have.

Alector Stock Falls After Flashing 12-Month Data From Mid-Stage Trial In Frontotemporal Dementia Patients

AL001 Successfully Restored Progranulin to Normal Levels in FTD-GRN Patients

Alector Presents 12-Month Results from the INFRONT-2 Phase 2 Open-label Clinical Study of AL001 for the Treatment of Symptomatic Frontotemporal Dementia Patients with a Progranulin Mutation

Oral Presentation to Highlight Data from the Ongoing Phase 2 Study of AL001 in FTD-GRN Company to Host Analyst and Investor Conference Call on July 29 at 1:00 p.m. ET

Alector to Present New Data from Frontotemporal Dementia and Alzheimer's Disease Programs at the 2021 Alzheimer's Association International Conference

As of late, it has definitely been a great time to be an investor in Alector, Inc. (ALEC).

Alector's (ALEC) Shares March Higher, Can It Continue?

The company has yet another fine July trading day thanks to a Citigroup analyst.

Why Alector Zoomed 12% Higher Today

GlaxoSmithKline

Glaxo (GSK) and Alector set to co-develop and co-commercialize AL001 and AL101 for neurodegenerative diseases. Glaxo issues a formal response to activist hedge investor, Elliott's call for board changes.

Glaxo (GSK)/Alector Ink Deal for Neurodegenerative Indications

Alector (ALEC) signs a global collaboration deal with Glaxo to co-develop/commercialize two monoclonal antibodies - AL001 and AL101 ??? for treating various neurodegenerative diseases.

Alector (ALEC) Up on Tie-Up With Glaxo for Neurological Diseases

Alector (ALEC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Alector (ALEC) Stock Jumps 57.1%: Will It Continue to Soar?

It's not every day that a small biotech announces a major collaboration deal with a deep-pocketed pharmaceutical giant.

Why Alector Blasted Higher Today

One of these companies is making big waves.

News for Alector Inc Stock (ALEC)